News

Search For News


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

1. Exscientia Enters Strategic Drug Discovery Collaboration with GSK. Pre

Exscientia Enters Strategic Drug Discovery Collaboration with GSK. Pre-clinical Collaboration Focused on up to 10 Targets Nominated by GSK02/07/2017Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce it has entered into a strategic drug discovery collaboration with GlaxoSmithKline (GSK). During this collaboration, Exscientia will apply its AI enabled platform and combine this with the expertise of GSK, in order to disco


2. Oxford BioMedica Announces a Major Supply Agreement

Oxford BioMedica Announces a Major Supply Agreement06/07/2017Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today announces that it has signed an agreement with Novartis for the commercial and clinical supply of lentiviral vectors used to generate CTL019 (tisagenlecleucel) and other undisclosed Chimeric Antigen Receptor T cell (CART) products. The agreement builds on the collaboration announced between the Group


3. Freeline Therapeutics Appoints Anne Prener as Chief Executive Officer

Freeline Therapeutics Appoints Anne Prener as Chief Executive Officer10/07/2017Freeline Therapeutics (“Freeline”), a biopharmaceutical company focused on the development of curative gene therapies for bleeding and other debilitating disorders, today announced that Anne Prener has been appointed Chief Executive Officer.Anne has extensive experience in drug development and commercialisation with a specific focus on gene therapy and rare diseases. Anne joins Freeline from Gyroscope Ther


4. K Biobank Makes Available Vast Trove of Genetics Information

K Biobank Makes Available Vast Trove of Genetics Information20/07/2017A vast trove of genetic data on half a million Britons becomes available today (20th July 2017) for research into a wide range of diseases.The information is released by UK Biobank to approved researchers having been checked and strengthened over the past two years by genetics experts at Oxford University.All 500,000 UK Biobank participants provided samples of blood for long term storage and analysis, including genetic, when t


5. AstraZeneca plc. (7/27/17).

AstraZeneca plc. "Press Release: H1 2017 Results". 27/07/2017Pascal Soriot, Chief Executive Officer, commenting on the results said:“Our performance in the first half was in line with expectations as we experience the loss of exclusivity of Crestor and Seroquel XR in the US. We continued to deliver transformative science across the pipeline, particularly in Oncology. Imfinzi was launched in bladder cancer while we published practice-changing data in breast cancer for Lynparza, our fir



Page 28 of 30 ( 148 results in total )
© Catalyst Innovation Portal 2018